B

Biovaxys Technology Corp
CNSX:BIOV

Watchlist Manager
Biovaxys Technology Corp
CNSX:BIOV
Watchlist
Price: 0.19 CAD -5%
Market Cap: 8.1m CAD

Biovaxys Technology Corp
Investor Relations

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-11-21. The firm is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

Show more
Loading
BIOV
S&P TSX Composite Index (Canada)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. James Christopher Passin
Co-Founder, CEO, & Director
No Bio Available
Mr. Kenneth E. Kovan
Co-Founder, President & COO
No Bio Available
Dr. David Berd M.D.
Co-Founder & Chief Medical Officer
No Bio Available
Mr. Christopher P. Cherry
Chief Financial Officer
No Bio Available

Contacts

Address
BRITISH COLUMBIA
Vancouver
503 - 905 West Pender Street, 905 West Pender Street,
Contacts
+16464527000.0
biovaxys.com